SUBSCRIBE
SUBSCRIBE

Apnimed

NEWS
American dollars grow on the garden bed on a meadow
Drug Development
Money on the Move: April Showers Bring May Flowers—and Funding
Dianthus Therapeutics, Enavate Sciences and CytoTronics were all launched with this recent wave of investor funding. For that and more, continue reading.
May 4, 2022
 · 
4 min read
 · 
Hannah Chudleigh
JOBS
IN THE PRESS
Genetown
Apnimed to Present at the Jefferies Healthcare Conference
June 6, 2022
 · 
2 min read
Genetown
Apnimed Announces $62.5 Million Series C Financing to Advance Development of Novel Pharmaceutical Treatments for Obstructive Sleep Apnea (OSA) and Related Sleep Disorders
May 4, 2022
 · 
5 min read
Genetown
Apnimed to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 5, 2022
 · 
2 min read
Genetown
Apnimed to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 10, 2022
 · 
2 min read
Genetown
Apnimed Study APC-004 Phase 2 Data to be Presented at World Sleep 2022
March 9, 2022
 · 
4 min read
Genetown
Apnimed to Participate in the SVB Leerink Global Healthcare Conference
February 7, 2022
 · 
2 min read
Genetown
Apnimed to Present at the 40th Annual JP Morgan Healthcare Conference
January 6, 2022
 · 
2 min read
Drug Development
Apnimed Announces Dosing of First Patient in Phase 2 MARIPOSA Confirmatory Trial of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea (OSA)
December 16, 2021
 · 
5 min read
Drug Development
Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Investigational Treatment for the Disease
October 13, 2021
 · 
6 min read
Drug Development
Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment
October 13, 2021
 · 
7 min read
Load More